Reunião Anual do AAN: Highlights em doenças neurodegerativas
Escrito por: Zilda Machado Meneghelo em 3 de maio de 2022
1 min de leitura
Referências
Sharon Cohen, MD, et al., Item-Level Analysis of Clinical Measures in Patients With Early Symptomatic Alzheimer’s Disease Following Treatment With High-Dose Aducanumab in the Phase 3 EMERGE Study. Presented at 2022 AAN Annual Meeting.
Ahmed Chenna, PhD et al., Quantitation of Nervous System Proteins NF-L, t-Tau, p-Tau181, Aß1-42, Aß1-40, GFAP and Inflammatory Cytokines IL-6, IL-10, TNFa in Alzheimer’s Disease Plasma. Presented at 2022 AAN Annual Meeting.
Raumin Shawn Neuville et al., One Hundred Centenarians: Brain Pathology and Relationship to Dementia in The 90+ Study. Presented at 2022 AAN Annual Meeting.
Ramakrishna Nirogi, PhD et al., Masupirdine (SUVN-502), A Serotonin Receptor Sub-Type 6 Antagonist for the Potential Treatment of Agitation and Psychosis in Patients with Dementia of Alzheimer’s Type. Presented at 2022 AAN Annual Meeting.